➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Express Scripts
Merck
Dow
Harvard Business School

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TENOFOVIR ALAFENAMIDE FUMARATE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Tenofovir Alafenamide Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036634 ↗ A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients Completed Gilead Sciences Phase 1/Phase 2 2002-03-01 This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
NCT01497899 ↗ Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 2 2011-12-01 This study will evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗ D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults Completed Gilead Sciences Phase 2 2012-04-01 This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tenofovir Alafenamide Fumarate

Condition Name

Condition Name for Tenofovir Alafenamide Fumarate
Intervention Trials
Chronic Hepatitis B 11
Hiv 11
HIV-1 Infection 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tenofovir Alafenamide Fumarate
Intervention Trials
Hepatitis B 23
Hepatitis 22
Hepatitis A 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tenofovir Alafenamide Fumarate

Trials by Country

Trials by Country for Tenofovir Alafenamide Fumarate
Location Trials
United States 287
China 65
Canada 41
Australia 14
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tenofovir Alafenamide Fumarate
Location Trials
California 20
Florida 17
New York 15
Texas 14
Missouri 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tenofovir Alafenamide Fumarate

Clinical Trial Phase

Clinical Trial Phase for Tenofovir Alafenamide Fumarate
Clinical Trial Phase Trials
Phase 4 15
Phase 3 23
Phase 2 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tenofovir Alafenamide Fumarate
Clinical Trial Phase Trials
Recruiting 22
Not yet recruiting 18
Active, not recruiting 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tenofovir Alafenamide Fumarate

Sponsor Name

Sponsor Name for Tenofovir Alafenamide Fumarate
Sponsor Trials
Gilead Sciences 30
Third Affiliated Hospital, Sun Yat-Sen University 5
National Institute of Allergy and Infectious Diseases (NIAID) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tenofovir Alafenamide Fumarate
Sponsor Trials
Other 54
Industry 38
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Baxter
Dow
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.